Forbes April 15, 2021
It’s hard to flawlessly churn out billions of doses of drugs – and we aren’t doing a great job of it. A Midas List VC pulled together a dream team that says it’s come up with a better, faster way.
It’s all come down to Pfizer and Moderna. With Johnson & Johnson’s “one-and-done” shot on pause, America’s race against the virus and its variants now relies on our ability to flawlessly manufacture hundreds of millions of doses of the new mRNA vaccines – at warp speed. And previous quality control issues at a Pfizer plant, on top of Emergent BioSolutions fiasco with the J&J vaccine, are a stark reminder that manufacturing medicine is not easy.
Robert Nelsen, the top biotech...